发明名称 |
Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathway |
摘要 |
The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the Ras/Raf/Mek pathway for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human. |
申请公布号 |
US9241939(B2) |
申请公布日期 |
2016.01.26 |
申请号 |
US201414576314 |
申请日期 |
2014.12.19 |
申请人 |
Novartis AG |
发明人 |
Garcia-Echeverria Carlos;Maira Sauveur-Michel;Stuart Darrin;Wee Susan;Fritsch Christine;Nagel Tobi |
分类号 |
A61K31/497;A61K31/4745;A61K31/4188;A61K45/06;A61K31/166;A61K31/437;A61K31/4439;A61K31/5377 |
主分类号 |
A61K31/497 |
代理机构 |
|
代理人 |
Rueck Sandra |
主权项 |
1. A method of treating a warm-blooded animal having a pancreatic cancer, comprising simultaneously, sequentially or separately administering to said animal (a) a phosphoinositide 3-kinase inhibitor compound selected from 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine and (b) a compound which modulates Mek kinase activity selected from ARRY142886/AZD6244, ARRY162, and GSK1120212, wherein the active ingredients are present in free form or in the form of a pharmaceutically acceptable salt thereof, in a quantity which is therapeutically effective against said proliferative disease. |
地址 |
Basel CH |